GlassScriptPhysician profile
Manish Shah
NPI 1558328625
$4,316.35
in general payments reported to CMS, 2019-2025
33 companies · $732 in 2025
The $732 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $822 · 2020: $343 · 2021: $759 · 2022: $443 · 2023: $890 · 2024: $328 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,330 · Travel and Lodging: $620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,330.02 |
| Travel and Lodging | $620.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,085.92 | 2019-2025 | Veozah, Xtandi |
| Medtronic, INC. | $781.76 | 2021-2025 | Sinuva, Interstim, Selectsecure |
| Coloplast Corp | $263.90 | 2019-2025 | |
| Janssen Biotech, INC. | $219.45 | 2019-2025 | Erleada, Akeega, Balversa |
| Pfizer INC. | $207.35 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $173.06 | 2019-2025 | |
| Ethicon US, LLC | $169.24 | 2020-2025 | Evarrest, Vistaseal, Echelon Flex |
| Allergan, INC. | $161.58 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $143.54 | 2025 | Adstiladrin |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $135.63 | 2019 | |
| Sumitomo Pharma America, INC. | $107.01 | 2023-2025 | Gemtesa, Orgovyx |
| Endo Pharmaceuticals INC. | $88.83 | 2020-2024 | Xiaflex |
| Urogen Pharma, INC. | $88.35 | 2024-2025 | |
| Tolmar Pharmaceuticals, INC. | $81.77 | 2019-2022 | |
| Dendreon Pharmaceuticals LLC | $76.71 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $68.33 | 2022-2025 | Itind System, Uretero-Reno Videoscope, Cysto-Nephro Videoscope |
| Axonics, INC. | $60.19 | 2020-2023 | Axonics, Bulkamid |
| Travere Therapeutics, INC. | $51.46 | 2019-2021 | |
| Procept Biorobotics Corporation | $42.22 | 2024 | Aquabeam System |
| Boston Scientific Corporation | $41.56 | 2019-2025 | Axonics |
| Accord Healthcare, INC. | $40.71 | 2025 | |
| Teleflex LLC | $33.26 | 2025 | Barrigel |
| Verity Pharmaceuticals INC. | $27.45 | 2025 | Trelstar |
| Endo USA, INC. | $26.30 | 2025 | Xiaflex |
| Tolmar, INC. | $21.70 | 2023 | |
| Progenics Pharmaceuticals, INC. | $19.84 | 2025 | |
| Urovant Sciences INC | $16.12 | 2022 | |
| Myriad Genetic Laboratories, INC. | $15.85 | 2021 | |
| Myovant Sciences INC. | $14.79 | 2021 | |
| Bluewind Medical | $14.39 | 2024 | Revi |
| Antares Pharma, INC. | $13.99 | 2022 | |
| Photocure INC | $13.13 | 2021 | |
| Therapeuticsmd, INC. | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.